https://scholars.lib.ntu.edu.tw/handle/123456789/502669
標題: | GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution | 作者: | HSIN-AN HOU YUN-CHU LIN Kuo Y.-Y. WEN-CHIEN CHOU CHIEN-CHIN LIN Liu C.-Y. Chen, Chien-Yuan LIANG-IN LIN Tseng M.-H. Huang C.-F. Chiang Y.-C. Liu M.-C. Liu C.-W. JIH-LUH TANG MING YAO SHANG-YI HUANG BOR-SHENG KO SZU-CHUN HSU SHANG-JU WU WOEI TSAY YAO-CHANG CHEN HWEI-FANG TIEN |
公開日期: | 2015 | 卷: | 94 | 期: | 2 | 起(迄)頁: | 211-221 | 來源出版物: | Annals of Hematology | 摘要: | Recently, mutations of the GATA binding protein 2 (GATA2) gene were identified in acute myeloid leukemia (AML) patients with CEBPA double mutations (CEBPAdouble-mut), but the interaction of this mutation with other genetic alterations and its dynamic changes during disease progression remain to be determined. In this study, 14 different missense GATA2 mutations, which were all clustered in the highly conserved N-terminal zinc finger 1 domain, were identified in 27.4, 6.7, and 1?% of patients with CEBPAdouble-mut, CEBPAsingle-mut, and CEBPA wild type, respectively. All but one patient with GATA2 mutation had concurrent CEBPA mutation. GATA2 mutations were closely associated with younger age, FAB M1 subtype, intermediate-risk cytogenetics, expression of HLA-DR, CD7, CD15, or CD34 on leukemic cells, and CEBPA mutation, but negatively associated with FAB M4 subtype, favorable-risk cytogenetics, and NPM1 mutation. Patients with GATA2 mutation had significantly better overall survival and relapse-free survival than those without GATA2 mutation. Sequential analysis showed that the original GATA2 mutations might be lost during disease progression in GATA2-mutated patients, while novel GATA2 mutations might be acquired at relapse in GATA2-wild patients. In conclusion, AML patients with GATA2 mutations had distinct clinic-biological features and a favorable prognosis. GATA2 mutations might be lost or acquired at disease progression, implying that it was a second hit in the leukemogenesis of AML, especially those with CEBPA mutation. ? 2014, Springer-Verlag Berlin Heidelberg. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/502669 | ISSN: | 0939-5555 | DOI: | 10.1007/s00277-014-2208-8 | SDG/關鍵字: | antineoplastic agent; CCAAT enhancer binding protein alpha; CD15 antigen; CD34 antigen; CD7 antigen; HLA DR antigen; transcription factor GATA 2; CCAAT enhancer binding protein; CEBPA protein, human; GATA2 protein, human; transcription factor GATA 2; acute myeloblastic leukemia; adult; age distribution; aged; amino terminal sequence; antigen expression; Article; cancer chemotherapy; cancer patient; cancer recurrence; cancer risk; cancer survival; chromosome aberration; controlled study; cytogenetics; disease course; exon; female; follow up; GATA2 gene; gene; genetic risk; human; human cell; induction chemotherapy; karyotype; leukemia cell; leukemia remission; leukemogenesis; major clinical study; male; middle aged; missense mutation; mutational analysis; overall survival; priority journal; recurrence free survival; recurrence risk; risk assessment; sequential analysis; survival rate; treatment response; young adult; zinc finger motif; acute disease; adolescent; genetics; genotype; Kaplan Meier method; Leukemia, Erythroblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; mutation; pathology; prognosis; tumor recurrence; very elderly; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; CCAAT-Enhancer-Binding Proteins; Chromosome Aberrations; Disease Progression; Follow-Up Studies; GATA2 Transcription Factor; Genotype; Humans; Kaplan-Meier Estimate; Karyotype; Leukemia, Erythroblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Young Adult |
顯示於: | 醫學檢驗暨生物技術學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。